

# Atul Bhardwaj

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/691952/publications.pdf>

Version: 2024-02-01

34  
papers

12,356  
citations

471061

17  
h-index

395343

33  
g-index

39  
all docs

39  
docs citations

39  
times ranked

34040  
citing authors

#	ARTICLE	IF	CITATIONS
1	In situ click chemistry generation of cyclooxygenase-2 inhibitors. Nature Communications, 2017, 8, 1.	5.8	10,736
2	Combined Measurement of the Higgs Boson Mass in $pp \rightarrow \mu\mu\gamma\gamma$ Collisions at $\sqrt{s} = 7$ and $8$ TeV with the ATLAS and CMS Experiments. Physical Review Letters, 2015, 114, 191803.	2.9	1,062
3	Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant <i>Enterococcus</i> . Journal of Medicinal Chemistry, 2020, 63, 9540-9562.	2.9	57
4	Mono-, Di-, and Triaryl Substituted Tetrahydropyrans as Cyclooxygenase-2 and Tumor Growth Inhibitors. Synthesis and Biological Evaluation. Journal of Medicinal Chemistry, 2010, 53, 3707-3717.	2.9	45
5	N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: Synthesis and biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2154-2159.	1.0	41
6	Hybrid fluorescent conjugates of COX-2 inhibitors: Search for a COX-2 isozyme imaging cancer biomarker. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 163-168.	1.0	37
7	Fluorophore-Labeled Cyclooxygenase Inhibitors for the Imaging of Cyclooxygenase Overexpression in Cancer: Synthesis and Biological Studies. ChemMedChem, 2014, 9, 109-116.	1.6	36
8	Synthesis and Biological Investigations of Nitric Oxide Releasing Nateglinide and Meglitinide Type II Antidiabetic Prodrugs: In-Vivo Antihyperglycemic Activities and Blood Pressure Lowering Studies. Journal of Medicinal Chemistry, 2012, 55, 7883-7891.	2.9	33
9	Design, Synthesis, and Evaluation of an $^{18}\text{F}$ -Labeled Radiotracer Based on Celecoxib-NBD for Positron Emission Tomography (PET) Imaging of Cyclooxygenase-2 (COX-2). ChemMedChem, 2015, 10, 1635-1640.	1.6	27
10	1-Toluene-sulfonyl-3-[(3-hydroxy-5-substituted)- $\beta$ -butyrolactone]-indoles: Synthesis, COX-2 inhibition and anti-cancer activities. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 85-89.	1.0	24
11	Rofecoxib Analogues Possessing a Nitric Oxide Donor Sulfohydroxamic Acid ( $\text{SO}_2\text{NHOH}$ ) Cyclooxygenase-2 Pharmacophore: Synthesis, Molecular Modeling, and Biological Evaluation as Anti-inflammatory Agents. ChemMedChem, 2012, 7, 62-67.	1.6	24
12	Aspirin Analogues as Dual Cyclooxygenase-2/5-Lipoxygenase Inhibitors: Synthesis, Nitric Oxide Release, Molecular Modeling, and Biological Evaluation as Anti-inflammatory Agents. ChemMedChem, 2012, 7, 144-150.	1.6	20
13	$\text{O}^2$ -Sulfonylethyl Protected Isopropylamine Diazen-1-ium-1,2-diolates as Nitroxyl ( $\text{HNO}$ ) Donors: Synthesis, $\beta$ -Elimination Fragmentation, $\text{HNO}$ Release, Positive Inotropic Properties, and Blood Pressure Lowering Studies. Journal of Medicinal Chemistry, 2012, 55, 10262-10271.	2.9	19
14	Mechanism of Action of Key Enzymes Associated with Cancer Propagation and their Inhibition by Various Chemotherapeutic Agents. Mini-Reviews in Medicinal Chemistry, 2008, 8, 388-398.	1.1	18
15	Design, synthesis and evaluation of tetrahydropyran based COX-1/2 inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 1278-1287.	2.6	18
16	Synthesis of highly functionalized barbituric acids and study of their interactions with p-glycoprotein and $\text{Mg}^{2+}$ - Potential candidates for multi drug resistance modulation. European Journal of Medicinal Chemistry, 2010, 45, 1256-1262.	2.6	18
17	Cardiovascular Properties of a Nitric Oxide Releasing Rofecoxib Analogue: Beneficial Anti-hypertensive Activity and Enhanced Recovery in an Ischemic Reperfusion Injury Model. ChemMedChem, 2012, 7, 1365-1368.	1.6	17
18	NSAIDs do not require the presence of a carboxylic acid to exert their anti-inflammatory effect - why do we keep using it?. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1018-1028.	2.5	17

#	ARTICLE	IF	CITATIONS
19	Glutathione <i>S</i> -Transferase ï€-Activatable <i>O</i> <sup>2</sup> -(Sulfonylethyl Derived) Diazeniumdiolates Potently Suppress Melanoma in Vitro and in Vivo. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1833-1844.	2.9	17
20	Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 420-423.	1.0	16
21	1,4-Diaryl-substituted triazoles as cyclooxygenase-2 inhibitors: Synthesis, biological evaluation and molecular modeling studies. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 4288-4295.	1.4	14
22	Isomeric acetoxy analogs of celecoxib and their evaluation as cyclooxygenase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6074-6080.	1.0	11
23	Pyrimidine-based fluorescent COX-2 inhibitors: synthesis and biological evaluation. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 7250-7257.	1.5	11
24	Design and synthesis of [ <sup>125</sup> I]Pyrcoxib: A novel <sup>125</sup> I-labeled cyclooxygenase-2 (COX-2) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1516-1520.	1.0	7
25	Synthesis and Preclinical Evaluation of [ <sup>18</sup> F]SiFA-PSMA Inhibitors in a Prostate Cancer Model. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15671-15689.	2.9	6
26	Development of Fluorescence Imaging Probes for Labeling COX-1 in Live Ovarian Cancer Cells. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 798-804.	1.3	5
27	Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks?. <i>Future Medicinal Chemistry</i> , 2013, 5, 381-383.	1.1	4
28	The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor. <i>Synthetic Communications</i> , 2019, 49, 1436-1443.	1.1	4
29	In Cellulo Generation of Fluorescent Probes for Liveâ€Cell Imaging of Cyclooxygenaseâ€2. <i>Chemistry - A European Journal</i> , 2021, 27, 3326-3337.	1.7	4
30	Do nitric oxide-releasing drugs offer a potentially new paradigm for the management of cardiovascular risks in diabetes?. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 533-536.	0.6	3
31	A diazen-1-ium-1,2-diolate analog of 7-azabenzobicyclo[2.2.1]heptane: Synthesis, nitric oxide and nitroxyl release, in vitro hemodynamic, and anti-hypertensive studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2769-2774.	1.0	2
32	Design, Synthesis, and Evaluation of a Luminescent Cholesterol Mimic. <i>Journal of Organic Chemistry</i> , 2021, 86, 1612-1621.	1.7	2
33	Fluorine-18 Labeled Radioligands for PET Imaging of Cyclooxygenase-2. <i>Molecules</i> , 2022, 27, 3722.	1.7	1
34	Synthesis, binding affinity analysis, and <sup>18</sup> Fâ€radiosynthesis of small molecular weight HIFâ€1â€ binding compounds.. <i>ChemMedChem</i> , 2021, , .	1.6	0